Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+0.68%
$0.63
75% positive prob.
5-Day Prediction
+8.80%
$0.69
75% positive prob.
20-Day Prediction
+3.76%
$0.65
71% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q2 2026 | BUY | +0.68% | +8.80% | +3.76% | 50.0% | -29.53% |
| Q1 2026 | BUY | +1.58% | +10.63% | +9.25% | 100.0% | +22.73% |
| Q3 2025 | SELL | -4.35% | -10.50% | -16.88% | 99.9% | -5.90% |
SEC 8-K filings with transcript text
Aug 13, 2026 · 50% conf.
1D
+0.68%
$0.63
Act: -12.78%
5D
+8.80%
$0.69
Act: -29.53%
20D
+3.76%
$0.65
2 vnrx_ex991.htm
vnrx_ex991.htm
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for
Friday, August 14 at 8:30 a.m. U.S. Eastern Time
Henderson, Nevada, August 13, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces financial results and a business update for the second quarter of 2026. Volition management will host a conference call tomorrow, August 14 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below.
Cameron Reynolds, President and Group Chief Executive Officer, said:
“We have made strong progress across all of our product pillars throughout 2026 to date.
“We are currently in discussions, including undertaking technology evaluations, with more than a dozen of the world’s leading diagnostic and liquid biopsy companies where our goal is to enter into licensing agreements and other arrangements that will bring revenue in the form of up front milestone payments, royalties and/or other recurring revenue. Discussions are at various stages of the negotiation process across our different pillars with our laser focus on executing further licensing agreements.
“We announced our collaboration with Sysmex Corporation, a global leader in the field of in vitro diagnostics for hemostasis and thrombosis, among other diseases, where Neutrophil Extracellular Traps ("NETS") play such an important role.
“In May, we announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q® Vet feline prototype assay in detecting lymphoma in cats, our third species. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment. The feline test could greatly expand the market of our Nu.Q® Vet platform.
“We are working with our long-term collaborators at the Hospices Civils de Lyon, one of Europe's leading cancer centers, on the reimbursement submission for Nu.Q® Lung Cancer. Reimbursement is the last step on the path to the first use of Nu.Q® in routine clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives.
“We continue to add to our significant data rooms with published, submitted and confidential data across our product pillars. Most notably, we recently announced the publication of our first peer-reviewed paper demonstrating our breakthrough Capture-Seq™ liquid biopsy technology.
“The Total Addressable Markets1 (TAMs) for our technologies, on an annualized basis, are multi-billion-dollar opportunities (estimated at more than $27 billion across all of our product pillars), not only for Volition, but for our licensing partners. Volition has made strong progress, both clinically and commercially, and our technology is now poised to be used very widely in a broad range of clinical utilities.”
1
Financial Highlights
·
First half of 2026 revenue was $1.4 million, 112% growth over the first half of 2025
·
Revenue for the second quarter of 2026 was approximately $0.4 million, in line with the same period in 2025
·
Operating expenses for the second quarter of 2026 were 32% lower than the same quarter in 2025, reflecting the impact of our cost reduction program
·
Operating loss was $4.2 million for the second quarter of 2026, down 34% versus the comparable quarter in 2025
·
Net cash used in operating activities was $5.2 million for the second quarter of 2026, 18% lower than the same quarter in 2025
·
Receipts in the second quarter of 2026 included:
○
$1.2 million in net proceeds from equity sales through our at-the-market facility
○
$4.1 million in net proceeds from the issuance of shares and warrants in a confidentially marketed public offering
Event: VolitionRx Limited Second Quarter 2026 Earnings and Business Update Conference Call
Date: Friday, August 14, 2026
Time: 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time
U.S. & Canada Dial-in: 1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID: 13762190
Louise Batchelor, Group Chief Marketing & Communications Officer of Volition will host the call along with Cameron Reynolds, President and Group Chief Executive Officer and Terig Hughes, Group Chief Financial Officer. The call will provide an update on important events that have taken place in the second quarter of 2026, subsequent events and upcoming milestones.
A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until August 28, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay
May 14, 2026 · 100% conf.
1D
+1.58%
$2.23
Act: -5.91%
5D
+10.63%
$2.43
Act: +22.73%
20D
+9.25%
$2.40
Act: -37.27%
2 vnrx_ex991.htm
vnrx_ex991.htm
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for
Friday, May 15 at 8:30 a.m. U.S. Eastern Time
Henderson, Nevada, May 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces financial results and a business update for the first quarter 2026. Volition management will host a conference call tomorrow, May 15 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below.
Cameron Reynolds, President and Group Chief Executive Officer, said:
“We have made strong progress across all of our product pillars during the first quarter and indeed subsequent to quarter end.
“We announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q® Vet feline prototype assay in detecting lymphoma in cats, our third species. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment. The feline test could greatly expand the market of our Nu.Q® Vet platform.
“We are working with our long-term collaborators at the Hospices Civils de Lyon, one of Europe's leading cancer centers, on the reimbursement submission for Nu.Q® Lung Cancer. Reimbursement is the last step on the path to the first use of Nu.Q® in routine clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives.
“We reported two new, potentially large, clinical use cases for our Nu.Q® NETs assay beyond sepsis. In conjunction with the Mayo Clinic1, we demonstrated Nu.Q® NETs’ potential clinical utility in aiding early risk identification which could inform targeted preventive strategies in acute trauma care. We also demonstrated potential use for patient management of a chronic disease, Hidradenitis Suppurativa,2 which affects about 1% of the world’s population. Both use cases have the potential to be large markets.
“We are currently in discussions with more than a dozen of the world’s leading diagnostic and liquid biopsy companies where our goal is to enter into licensing agreements and other arrangements that will bring revenue in the form of up front milestone payments, royalties and/or other recurring revenue.
“We are delighted to have grown the commercial interest in the first quarter, particularly with regards to our Capture-Seq™ technology, with an increase in discussions, including for technical evaluations.
“Discussions are at various stages of the negotiation process across all our different pillars; our laser focus is on executing licensing agreements and we will update you as they progress.”
1
Financial Highlights
· Revenue for the first quarter was approximately $1.0 million, compared to $0.2 million for the same period in 2025.
· Operating loss was down 3% for the quarter versus the comparable quarter in 2025.
· Net cash used in operating activities was $5.3 million.
· Receipts in the quarter included:
○
$5.4 million in net proceeds from equity sales through our at-the-market facility,
○
$1.9 million in net proceeds from issuance of a convertible note and warrant, and
○
$1 million of non-dilutive funding from agencies of the Walloon Region, with an additional approximate $0.9 million expected to be received in tranches based on certain time and event milestones over the next 12 months.
2
Event:
VolitionRx Limited First Quarter 2026 Earnings and Business Update Conference Call
Date:
Friday, May 15, 2026
Time:
8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time
U.S. & Canada Dial-in: 1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID: 13760656
Louise Batchelor, Group Chief Marketing & Communications Officer of Volition will host the call along with Cameron Reynolds, President and Group Chief Executive Officer and Terig Hughes, Group Chief Financial Officer. The call will provide an update on important events that have taken place in the first quarter of 2026, subsequent events and upcoming milestones.
A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until May 29, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13760656.
1.
Navarro, Sergio M. et al, Circulating Nucleosomes Are Elevated In Trauma Patients With Venous Thromboembolism: A Prospective Case-Cohort Study. SHOCK Journal, March 2026
2. PrePrint
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcom
Mar 31, 2026
2 vnrx_ex991.htm
vnrx_ex991.htm
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for
Wednesday, April 1 at 8:30 a.m. U.S. Eastern Time
Henderson, Nevada, March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces financial results and a business update for the full fiscal year 2025. Volition management will host a conference call tomorrow, April 1 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below.
Cameron Reynolds, President and Group Chief Executive Officer, said:
“We set out over fifteen years ago to help save lives and improve outcomes for millions of patients worldwide, and I could not be prouder of the progress we are making towards that goal.
“In 2025 we not only received our first order for the Nu.Q® Cancer assays for clinical certification ahead of routine clinical use in lung cancer, but we also announced the inclusion of our Nu.Q® NETs assay in a real-world interventional evaluation of early detection of sepsis, in a government-backed program (~$7.3 million) in France.
“Cancer and sepsis are leading causes of death, accounting for approximately one third of deaths worldwide. Our tests are about to be used in both these devastating diseases, to help save lives in real world hospital settings: an extremely proud moment for our entire team.
“Our goal is to secure a range of licensing agreements in the human diagnostics space and to that end we are in discussions with around 10 of the world’s leading diagnostic and liquid biopsy companies and are at various stages of the process across our different pillars, ranging from due diligence to tech transfer, to evaluation of clinical samples, to contract negotiation. We anticipate further human licensing deals and will update on progress as they are completed.
“I believe we will look back on 2025, this first quarter of 2026 and indeed in time, the next few quarters, as transformational for the company.”
Financial Highlights
· Finished the year strongly with year over year revenue growth for Q4 of 133%.
· Full-year revenue for 2025 was $1.7 million, representing growth of 40% over the previous year.
· Operating expenses for the year were down $4.8 million, or 17% compared to last year.
· Net loss was down 14% for the year versus 2024.
· Net cash used in operating activities was $19.7 million for the year, down 24%.
· Subsequent to year end, we received:
○
$5.4 million in net proceeds from equity sales through our at-the-market facility,
○
$1.9 million in net proceeds from issuance of a convertible note and warrant, and
○
$1.0 million of non-dilutive funding from agencies of the Walloon Region, with an additional approximate $0.9 million expected to be received in tranches based on certain time and event milestones over the next 12 months.
1
Event:
VolitionRx Limited Full Fiscal Year 2025 Earnings and Business Update Conference Call
Date:
Wednesday, April 1, 2026
Time:
8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time
U.S. & Canada Dial-in: 1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID: 13759627
Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Terig Hughes, Group Chief Financial Officer, Dr. Andrew Retter, Medical Consultant and Dr. Jake Micallef, Chief Scientific Officer. The call will provide an update on important events that have taken place in 2025, subsequent events and upcoming milestones.
A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until April 15, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13759627.
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
Th
Nov 13, 2025 · 100% conf.
1D
-4.35%
$0.34
Act: -6.60%
5D
-10.50%
$0.32
Act: -5.90%
20D
-16.88%
$0.29
Act: -24.12%
vnrx_8k.htm0000093314false00000933142025-11-132025-11-13iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): November 13, 2025
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware
001-36833
91-1949078
(State or other jurisdiction
(Commission
(IRS Employer
of Incorporation)
File Number)
Identification Number)
1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014
(Address of principal executive offices and Zip Code)
+1 (512) 774-8930
(Registrant’s telephone number, including area code )
Not applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock,par value $0.001 per share
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Form 8-K Current Report
Item 2.02. Results of Operations and Financial Condition.
The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On November 13, 2025, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended September 30, 2025. The Company also confirmed its conference call to be held on November 14, 2025 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated November 13, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)
2
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date November 13, 2025 By: /s/ Cameron Reynolds
Cameron Reynolds
Chief Executive Officer & President
3
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated November 13, 2025.
4
Oct 14, 2025 · 100% conf.
1D
-4.35%
$0.34
Act: -6.60%
5D
-10.50%
$0.32
Act: -5.90%
20D
-16.88%
$0.29
Act: -24.12%
vnrx_8k.htm0000093314false00000933142025-10-102025-10-10iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): October 10, 2025
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware
001-36833
91-1949078
(State or other jurisdiction
(Commission File Number)
(IRS Employer
of Incorporation)
Identification Number)
1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 (Address of principal executive offices and zip code)
+1 (646) 650-1351 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed from last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock, par value $0.001 per share
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On October 10, 2025, VolitionRx Limited (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Newbridge Securities Corporation (the “Underwriter”), relating to an underwritten public offering of 11,550,000 shares (the “Closing Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), together with accompanying common stock purchase warrants to purchase up to an aggregate of 11,550,000 shares of Common Stock (the “Closing Warrants”) at a combined offering price to the public of $0.52 per share of Common Stock and accompanying common stock warrant to purchase one share of Common Stock, including $0.01 per common stock warrant, less an underwriting commission of 7.0% (the “Offering”). Under the terms of the Underwriting Agreement, the Company also granted the Underwriter a 30-day option to purchase up to an additional 1,732,500 shares of Common Stock (the “Option Shares” and, together with the Closing Shares, the “Shares”) as well as accompanying common stock purchase warrants to purchase up to an aggregate of 1,732,500 shares of Common Stock (the “Option Warrants” and collectively with the Closing Warrants, the “Warrants”) at the same price per share and accompanying warrant. The Shares and the Warrants are referred to herein as the “Securities.”
The Warrants have an exercise price of $0.60 per share, subject to adjustment as provided for therein, are exercisable immediately and are exercisable for a period of five years from the closing of the Offering. The Warrants may only be exercised on a cashless basis if there is no registration statement registering, or the prospectus contained therein is not available for, the issuance of the shares underlying the Warrants to the holder. The Company is prohibited from effecting an exercise of any Warrants to the extent that such exercise would result in the number of shares of Common Stock beneficially owned by such holder and its affiliates exceeding 4.99% (or 9.99% at election of the holder) of the total number of shares of Common Stock outstanding immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder’s election not to exceed 9.99%. The Company also entered into a warrant agent agreement with the Company’s transfer agent, VStock Transfer LLC (the “Warrant Agent”), which will act as warrant agent for the Company, setting forth certain terms and conditions with respect to the Warrant Agent’s service as warrant agent for the Warrants (the “Warrant Agent Agreement”).
The Company agreed to reimburse the Underwriter for up to $100,000 of its reasonable, necessary, and documented out-of-pocket expenses incurred in connection with the Offering, including the fees and expenses of counsel to the Underwriter
Aug 14, 2025
vnrx_8k.htm0000093314false00000933142025-08-142025-08-14iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): August 14, 2025
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware
001-36833
91-1949078
(State or other jurisdiction
(Commission
(IRS Employer
of Incorporation)
File Number)
Identification Number)
1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 (Address of principal executive offices and Zip Code)
+1 (646) 650-1351 (Registrant’s telephone number, including area code )
Not applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock,par value $0.001 per share
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 ofthe Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Form 8-K Current Report
Item 2.02. Results of Operations and Financial Condition.
The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On August 14, 2025, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended June 30, 2025. The Company also confirmed its conference call to be held on August 15, 2025 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated August 14, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)
2
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date August 14, 2025 By: /s/ Cameron Reynolds
Cameron Reynolds
Chief Executive Officer & President
3
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated August 14, 2025.
4
May 15, 2025
vnrx_8k.htm0000093314false00000933142025-05-152025-05-15iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): May 15, 2025
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware
001-36833
91-1949078
(State or other jurisdiction
(Commission
(IRS Employer
of Incorporation)
File Number)
Identification Number)
1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014
(Address of principal executive offices and Zip Code)
+1 (646) 650-1351
(Registrant’s telephone number, including area code )
Not applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock,par value $0.001 per share
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Form 8-K Current Report
Item 2.02. Results of Operations and Financial Condition.
The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On May 15, 2025, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended March 31, 2025. The Company also confirmed its conference call to be held on May 16, 2025 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated May 15, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)
2
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date May 15, 2025 By: /s/ Cameron Reynolds
Cameron Reynolds
Chief Executive Officer & President
3
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated May 15, 2025.
4
Mar 31, 2025
vnrx_8k.htm0000093314false00000933142025-03-312025-03-31iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): March 31, 2025
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware
001-36833
91-1949078
(State or other jurisdiction
(Commission
(IRS Employer
of Incorporation)
File Number)
Identification Number)
1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 (Address of principal executive offices and Zip Code)
+1 (646) 650-1351 (Registrant’s telephone number, including area code )
Not applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock,par value $0.001 per share
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Form 8-K Current Report
Item 2.02. Results of Operations and Financial Condition.
The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On March 31, 2025, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for its quarter and fiscal year ended December 31, 2024. The Company also confirmed its conference call to be held on March 31, 2025 at 4:30 p.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated March 31, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)
2
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 31, 2025 By: /s/ Cameron Reynolds
Cameron Reynolds
Chief Executive Officer & President
3
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated March 31, 2025.
4
Nov 14, 2024
vnrx_8k.htm0000093314false00000933142024-11-142024-11-14iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): November 14, 2024
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware 001-36833 91-1949078
(State or other jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification Number)
1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014
(Address of Principal Executive Offices) (Zip Code)
+1 (646) 650-1351 (Registrant’s telephone number, including area code)
Not applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock,par value $0.001 per share
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Form 8-K Current Report
Item 2.02. Results of Operations and Financial Condition.
The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On November 14, 2024, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended September 30, 2024. The Company also confirmed its conference call to be held on November 15, 2024 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated November 14, 2024.
104
Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)
2
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 14, 2024 By: /s/ Cameron Reynolds
Cameron Reynolds
Chief Executive Officer & President
3
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated November 14, 2024.
4
Aug 14, 2024
vnrx_8k.htm0000093314false00000933142024-08-142024-08-14iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): August 14, 2024
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware
001-36833
91-1949078
(State or other jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification Number)
1489 West Warm Springs Road, Suite 110 Henderson, Nevada
89014
(Address of Principal Executive Offices)
(Zip Code)
+1 (646) 650-1351 (Registrant’s telephone number, including area code )
Not applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock,par value $0.001 per share
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Form 8-K Current Report
Item 2.02. Results of Operations and Financial Condition.
The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On August 14, 2024, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended June 30, 2024. The Company also confirmed its conference call to be held on August 15, 2024 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated August 14, 2024.
104
Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)
2
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date August 14, 2024 By:/s/ Cameron Reynolds
Cameron Reynolds
Chief Executive Officer & President
3
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated August 14, 2024.
4
May 13, 2024
vnrx_8k.htm0000093314false00000933142024-05-132024-05-13iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): May 13, 2024
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware
001-36833
91-1949078
(State or other jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification Number)
1489 West Warm Springs Road, Suite 110 Henderson, Nevada
89014
(Address of Principal Executive Offices)
(Zip Code)
+1 (646) 650-1351 (Registrant’s telephone number, including area code )
Not applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock, par value $0.001 per share
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Form 8-K Current Report
Item 2.02. Results of Operations and Financial Condition.
The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On May 13, 2024, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended March 31, 2024. The Company also confirmed its conference call to be held on May 14, 2024 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated May 13, 2024.
104
Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)
2
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date May 13, 2024 By: /s/ Cameron Reynolds
Cameron Reynolds
Chief Executive Officer & President
3
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated May 13, 2024.
4
Mar 25, 2024
vnrx_8k.htm0000093314false00000933142024-03-252024-03-25iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): March 25, 2024
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware
001-36833
91-1949078
(State or other jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification Number)
1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 (Address of principal executive offices and Zip Code)
+1 (646) 650-1351 (Registrant’s telephone number, including area code )
Not applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock,par value $0.001 per share
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 ofthe Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Form 8-K Current Report
Item 2.02. Results of Operations and Financial Condition.
The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On March 25, 2024, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for its quarter and fiscal year ended December 31, 2023. The Company also confirmed its conference call to be held on March 26, 2024 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated March 25, 2024.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 25, 2024 By: /s/ Cameron Reynolds
Cameron Reynolds
Chief Executive Officer & President
3
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated March 25, 2024.
4
Nov 14, 2023
vnrx_8k.htm0000093314false00000933142023-11-142023-11-14iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): November 14, 2023
(Exact name of registrant as specified in its charter)
Delaware
001-36833
91-1949078
(State or other jurisdiction
(Commission File Number)
(IRS Employer
of Incorporation)
Identification Number)
1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 (Address of principal executive offices and Zip Code)
+1 (646) 650-1351 (Registrant’s telephone number, including area code )
Not applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock,par value $0.001 per share
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Form 8-K Current Report
Item 2.02. Results of Operations and Financial Condition.
The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On November 14, 2023, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended September 30, 2023. The Company also confirmed its conference call to be held on November 15, 2023 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated November 14, 2023.
104
Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)
2
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 14, 2023 By: /s/ Cameron Reynolds
Cameron Reynolds
Chief Executive Officer & President
3
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated November 14, 2023.
4
Aug 14, 2023
vnrx_8k.htm0000093314false00000933142023-08-142023-08-14iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): August 14, 2023
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware
001-36833
91-1949078
(State or other jurisdiction
(Commission
(IRS Employer
of Incorporation)
File Number)
Identification Number)
1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014
(Address of principal executive offices and Zip Code)
+1 (646) 650-1351
(Registrant’s telephone number, including area code )
Not applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock, par value $0.001 per share
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Form 8-K Current Report
Item 2.02. Results of Operations and Financial Condition.
The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On August 14, 2023, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended June 30, 2023. The Company also confirmed its conference call to be held on August 15, 2023 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated August 14, 2023.
104
Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)
2
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 14, 2023 By: /s/ Cameron Reynolds
Cameron Reynolds
Chief Executive Officer & President
3
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated August 14, 2023.
4
May 10, 2023
vnrx_8k.htm0000093314false00000933142023-05-102023-05-10iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): May 10, 2023
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware
001-36833
91-1949078
(State or other jurisdiction
(Commission File Number)
(IRS Employer
of Incorporation)
Identification Number)
1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014
(Address of principal executive offices and Zip Code)
+1 (646) 650-1351
(Registrant’s telephone number, including area code )
Not applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock, par value $0.001 per share
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐.
Form 8-K Current Report
Item 2.02. Results of Operations and Financial Condition.
The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On May 10, 2023, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended March 31, 2023. The Company also confirmed its conference call to be held on May 11, 2023 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated May 10, 2023.
104
Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)
2
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date May 10, 2023 By: /s/ Cameron Reynolds
Cameron Reynolds
Chief Executive Officer & President
3
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated May 10, 2023.
4
Mar 15, 2023
vnrx_8k.htm0000093314false00000933142023-03-152023-03-15iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): March 15, 2023
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware
001-36833
91-1949078
(State or other jurisdiction
(Commission File Number)
(IRS Employer
of Incorporation)
Identification Number)
1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014
(Address of principal executive offices and Zip Code)
+1 (646) 650-1351
(Registrant’s telephone number, including area code )
Not applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock, par value $0.001 per share
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Form 8-K Current Report
Item 2.02. Results of Operations and Financial Condition.
The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On March 15, 2023, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for its quarter and fiscal year ended December 31, 2022. The Company also confirmed its conference call to be held on March 16, 2023 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated March 15, 2023.
104
Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)
2
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 15, 2023 By: /s/ Cameron Reynolds
Cameron Reynolds
Chief Executive Officer & President
3
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated March 15, 2023.
4
Feb 21, 2023
vnrx_8k.htm0000093314false00000933142023-02-172023-02-17iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): February 17, 2023
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware
001-36833
91-1949078
(State or other jurisdiction
(Commission File Number)
(IRS Employer
of Incorporation)
Identification Number)
1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 (Address of principal executive offices)
+1 (646) 650-1351 (Registrant’s telephone number, including area code )
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On February 17, 2023, VolitionRx Limited (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Newbridge Securities Corporation (the “Underwriter”) pursuant to which the Company agreed to issue and sell an aggregate of 4,300,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), to the Underwriter. The Firm Shares will be sold at a public offering price of $1.75 per share, less an underwriting commission of 7%. Under the terms of the Underwriting Agreement, the Company also granted the Underwriter a 30-day option to purchase up to an additional 645,000 shares of Common Stock (the “Option Shares” and, together with the Firm Shares, the “Shares”) offered in the offering at the same price per share as the Firm Shares. On February 19, 2023, the Underwriter exercised its option to purchase all of the Option Shares.
The net proceeds to the Company from the offering are expected to be approximately $8.0 million before deducting estimated offering expenses payable by the Company. The Company intends to use the proceeds from the offering for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions.
The offering is being made pursuant to the Company’s registration statement on Form S-3 (File No. 333-259783) previously filed with the Securities and Exchange Commission (“SEC”) on September 24, 2021, as amended on November 4, 2021, and declared effective by the SEC on November 8, 2021, as well as a prospectus supplement thereunder.
The offering of the Shares is expected to close on February 22, 2023 subject to customary closing conditions.
The Underwriting Agreement contains customary representations, warranties and covenants by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties, and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement.
A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K (the “Current Report”) and is incorporated herein by reference. The foregoing description of the terms of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit. A copy of the opinion of Stradling Yocca Carlson & Rauth, P.C. relating to the legality of the issuance and sale of the Shares in the offering is filed as Exhibit 5.1 to this Current Report.
Cautionary Note Regarding Forward-Looking Statements
This Current Report contains forwar
Nov 14, 2022
vnrx_8k.htm0000093314false00000933142022-11-142022-11-14iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): November 14, 2022
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware
001-36833
91-1949078
(State or other jurisdiction
(Commission
(IRS Employer
of Incorporation)
File Number)
Identification Number)
1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014
(Address of principal executive offices and Zip Code)
+1 (646) 650-1351
(Registrant’s telephone number, including area code )
Not applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock, par value $0.001 per share
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Form 8-K Current Report
Item 2.02. Results of Operations and Financial Condition.
The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On November 14, 2022, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended September 30, 2022. The Company also confirmed its conference call to be held on November 15, 2022 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated November 14, 2022.
104
Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)
2
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 14, 2022 By: /s/ Cameron Reynolds
Cameron Reynolds
Chief Executive Officer & President
3
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated November 14, 2022.
4
Aug 10, 2022
vnrx_8k.htm0000093314false00000933142022-08-102022-08-10iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): August 10, 2022
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware
001-36833
91-1949078
(State or other jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification Number)
1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 (Address of principal executive offices and Zip Code)
+1 (646) 650-1351 (Registrant’s telephone number, including area code )
Not applicable (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock, par value $0.001 per share
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Form 8-K Current Report
Item 2.02. Results of Operations and Financial Condition.
The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On August 10, 2022, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended June 30, 2022. The Company also confirmed its conference call to be held on August 11, 2022 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated August 10, 2022.
104
Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)
2
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 10, 2022 By: /s/ Cameron Reynolds
Cameron Reynolds
Chief Executive Officer & President
3
Exhibit Number
Description
99.1
Press Release of VolitionRx Limited, dated August 10, 2022.
4
Aug 2, 2022
vnrx_8k.htm0000093314false00000933142022-07-292022-07-29iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
Date of Report (Date of earliest event reported): July 29, 2022
VolitionRx Limited
(Exact name of registrant as specified in its charter)
Delaware
001-36833
91-1949078
(State or other jurisdiction
(Commission File Number)
(IRS Employer
of Incorporation)
Identification Number)
1489 West Warm Springs Road Suite 110 Henderson Nevada 89014 (Address of principal executive offices)
+1 (646) 650-1351 (Registrant’s telephone number, including area code )
13215 Bee Cave Parkway Suite 125, Galleria Oaks B Austin, Texas 78738
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on which Registered
Common Stock
NYSE American, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On July 29, 2022, VolitionRx Limited (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Newbridge Securities Corporation (the “Underwriter”) pursuant to which the Company agreed to issue and sell an aggregate of 3,000,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”) to the Underwriter. The Underwriter purchased the Firm Shares at a public offering price of $2.00 per share, less an underwriting commission of 7% for the sale of 2,687,500 shares to the public and 12,500 shares to a Company insider, and 3% for the sale of 300,000 shares to a Company insider. Under the terms of the Underwriting Agreement, the Company also granted the Underwriter a 30-day option to purchase up to an additional 450,000 shares of Common Stock (the “Option Shares” and, together with the Firm Shares, the “Shares”) at the same price per share as the Firm Shares. On August 1, 2022, the Underwriter exercised its option to purchase all of the Option Shares (such exercise, together with the Underwriter's purchase of the Firm Shares, the "Offering").
The net proceeds to the Company from the Offering are expected to be approximately $6.4 million before deducting estimated offering expenses payable by the Company. The Company intends to use the proceeds from the Offering for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions.
The Offering is being made pursuant to the Company’s registration statement on Form S-3 (File No. 333-259783), previously filed with the Securities and Exchange Commission (“SEC”) on September 24, 2021 and declared effective by the SEC on November 8, 2021, and a prospectus supplement thereunder.
The Offering of the Shares closed on August 2, 2022.
The Underwriting Agreement contains customary representations, warranties and covenants by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties, and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by such parties.
A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing description of the terms of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by referenc
This page provides VolitionRX Limited (VNRX) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on VNRX's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.